70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFátima Cardoso, Martine Piccart, Jean‐Yves Pierga et al.|New England Journal of Medicine|2016Cited by 2k
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Emiel J. Rutgers, Laura van ‘t Veer et al.|The Lancet Oncology|2021Cited by 355
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88